Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDDate | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
08/08/2023 | Q2 2023 | -$0.65 | -$0.74 | -0.09 | $0 | |
05/11/2023 | Q1 2023 | -$0.59 | -$0.42 | 0.17 | $0 | |
03/15/2023 | Q4 2022 | -$0.49 | -$0.50 | -0.01 | $0 | |
11/09/2022 | Q3 2022 | -$0.61 | -$0.53 | 0.08 | $0 | |
08/11/2022 | Q2 2022 | -$0.56 | -$0.58 | -0.02 | $0 | |
05/12/2022 | Q1 2022 | -$0.54 | -$0.50 | 0.04 | $0 | |
03/28/2022 | Q4 2021 | -$0.44 | $0 | |||
11/12/2021 | Q3 2021 | $0.50 | -$2.30 | -2.8 | $0 | |
06/29/2021 | Q2 2021 | -$0.21 | $1.13 M | |||
03/30/2021 | Q1 2021 | -$0.35 | $0 | |||
12/30/2020 | Q4 2020 | $0.00 | $188,000 | |||
09/29/2020 | Q3 2020 | -$0.26 | $225,000 |
DICE Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 9th, 2023 based off last year's report dates.
The conference call for DICE Therapeutics, Inc.'s latest earnings report can be listened to online.
The conference call transcript for DICE Therapeutics, Inc.'s latest earnings report can be read online.
DICE Therapeutics, Inc. (:DICE) has a recorded net income of $0. DICE Therapeutics, Inc. has generated $-2.07 earnings per share over the last four quarters.
DICE Therapeutics, Inc. (:DICE) has a price-to-earnings ratio of -22.94 and price/earnings-to-growth ratio is -0.23.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED